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Abstract
Background: Clinical studies of intraperitoneal chemotherapy with paclitaxel in patients of gastric cancer with peritoneal
carcinomatosis is well tolerated and effective, and rare cases of metastasis and recurrence have experienced during the
treatment. Disseminated carcinomatosis of the bone marrow is highly rare in gastric cancer and associated with a poor
prognosis.
Case presentation: A 59-year-old woman of gastric cancer with peritoneal carcinomatosis received five courses
of chemotherapy with intraperitoneal administration of paclitaxel, and laparoscopy showed disappearance of the
peritoneal carcinomatosis. She subsequently underwent total gastrectomy, and the histopathological findings showed
a complete response to the chemotherapy. Postoperatively, chemotherapy with intraperitoneal administration of
paclitaxel was continued for 30 months, without apparent recurrence. However, the gastric cancer recurred as
disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation, and we hence changed
the chemotherapy regimen to weekly irinotecan. Remission was achieved, and she did not experience any major
symptoms; however, she died 6 months after the diagnosis of disseminated carcinomatosis of the bone marrow.
Conclusions: Since intraperitoneal paclitaxel administration can strongly suppress peritoneal carcinomatosis of gastric
cancer, careful attention should be paid not only to peritoneal recurrence but also for rare site metastases, such as
bone marrow metastases.
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Background
Peritoneal carcinomatosis is the most frequent mode of
metastasis and recurrence in patients with gastric can-
cer. Clinical studies investigating the effects of intraperi-
toneal chemotherapy with paclitaxel (PTX) performed
by our group on such patients have shown that the treat-
ment is well tolerated and effective [1–3]. Moreover, we
have experienced rare cases of metastasis and recurrence
recently, such as leptomeningeal carcinomatosis [4] after
long-term control of peritoneal metastasis. Particularly,
bone marrow metastasis is highly rare in gastric cancer
[5], and disseminated carcinomatosis of the bone
marrow (DCBM) is known to be closely associated with
disseminated intravascular coagulation (DIC) and a poor
prognosis [5, 6]. Herein, we present a rare case of
DCBM originating from gastric cancer and developing
3 years after intraperitoneal chemotherapy with PTX
against peritoneal carcinomatosis.
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Case presentation
A 59-year-old woman was referred to our department for
intraperitoneal chemotherapy for gastric cancer with peri-
toneal carcinomatosis. She had already received two
courses of chemotherapy with S-1 plus cisplatin in the
previous hospital. Upper intestinal endoscopy showed
Borrmann type IV gastric cancer with ulceration at the
upper part of the stomach (Fig. 1a, b). Pathological diag-
nosis was poorly differentiated tubular adenocarcinoma
with the signet ring cell carcinoma. Staging laparoscopy
showed a thickened omentum due to carcinomatosis
(“omental cake”) and numerous disseminated nodules in
the whole abdominal cavity. An intraperitoneal access port
was implanted to allow for chemotherapy administration.
After the staging laparoscopy, she received five courses of
chemotherapy with intraperitoneal administration of PTX.
At first, two courses with intraperitoneal administration of
PTX, intravenous administration of oxaliplatin, and oral
S-1 were done. Then three courses with intraperitoneal
and intravenous administration of PTX and oral S-1 were
done. Oxaliplatin was administered intravenously at a dose
of 100 mg/m2 on day 1, and PTX was administered intra-
venously at a dose of 50 mg/m2 on day 1 and intraperito-
neally via the access port at a dose of 20 mg/m2 on days 1
and 8, respectively. PTX was diluted in 1 l normal saline
over 1 h. S-1 was administered orally twice daily at a dose
of 80 mg/m2 per day for 14 consecutive days, followed by
7 days without treatment. These chemotherapy in clinical
studies were approved by the institutional review board of
The University of Tokyo. Repeat laparoscopy showed dis-
appearance of the peritoneal carcinomatosis (Fig. 2a–d),
after which she underwent total gastrectomy with lymph-
adenectomy. Pathological examination revealed no viable
cancer cells remaining in the resected specimen (Fig. 3).
The patient received a total of 38 courses of chemotherapy
with intraperitoneal and intravenous administration of
PTX and oral S-1 after the gastrectomy, without apparent
metastasis or recurrence.
Two years and 6 months after the surgery, she experi-
enced lumbago, with increases in the carcinoembryonic
antigen (CEA), carbohydrate antigen (CA) 19-9, and
CA125 levels observed. Computed tomography showed
bone metastases at the thoracic to lumbar vertebrae. A
decreased platelet count was noted, indicating DIC,
and the patient was hence readmitted to our hospital.
At the time of admission, percutaneous bleeding was
observed in her forearm. Blood test showed hemoglobin,
9.9 g/dl; platelet count, 72,000/mm3; alkaline phosphat-
ase, 1969 IU/l; prothrombin time international normal-
ized ratio, 1.17; fibrinogen, 346 mg/dl; and fibrinogen
degradation products, 201.1 μg/ml. The patient was di-
agnosed as DIC, and treatment with gabexate mesilate
was initiated. The tumor marker levels, including CEA
(426.3 ng/ml) and CA19-9 (2413 IU/ml), were also further
increased. Bone scintigraphy and fluorodeoxyglucose-
positron emission tomography showed multiple bone
metastatic lesions in the thoracic to lumbar vertebrae, cos-
tae, sternum, iliac bone, scapulae, and femora (Fig. 4a–c).
DCBM from gastric cancer was clinically diagnosed, and
chemotherapy was immediately commenced with a regi-
men of weekly irinotecan (CPT-11). On day 1, intravenous
CPT-11 (100 mg/m2, 80 % dose) was administered, and
the regimen was repeated on a weekly basis. After three
courses of chemotherapy, she recovered from DIC with
relief of the lumbago. The same regimen was repeated in
an outpatient setting for 5 months. However, although the
patient did not show any signs of peritoneal recurrence,
the tumor markers increased and DIC developed again,
and the patient died of DCBM 3 years and 5 months after
the introduction of intraperitoneal chemotherapy.
Discussion
In the present case, gastric cancer metastasized to the
bone marrow and caused DCBM associated with DIC
3 years after intraperitoneal chemotherapy against peri-
toneal carcinomatosis of gastric cancer. DCBM is
Fig. 1 Upper gastrointestinal endoscopic studies of the patient. a Borrmann type IV gastric cancer with ulceration at the upper part of the
stomach was revealed. b Giant folds of the greater curvature and poor extension of the wall were shown at the middle part of the stomach
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uncommon in patients with gastric cancer; Kim et al.
reported that only 2.4 % of metastatic, unresectable, or
recurrent gastric cancers had confirmed bone marrow
metastasis [5]. And DCBM from solid tumors was
closely associated with DIC [6]. Jarcho et al. reported
an association between multiple bone metastases and
DIC in diffusely infiltrative gastric cancer as early as
1936 [7], and Brain et al. reported a close association
between mucin-forming cancer and DIC and/or micro-
angiopathic hemolytic anemia [8]. Later, Pasquini et al.
examined bone metastases from solid tumors with
hematological disorders, and the prognosis is very poor
[9]. This condition is called DCBM [5, 6].
In patients with DCBM and DIC from solid tumors,
gastric cancer accounts for the majority of cases [9].
DCBM is associated with various symptoms, including
bone pain, bleeding tendencies, anemia, general weak-
ness, and elevated levels of serum alkaline phosphatase
[5, 6, 10]. Macroscopic Borrmann types III and IV, his-
tologically poorly differentiated adenocarcinoma, youn-
ger age, highly advanced tumors, and primary tumors
in the upper part of the stomach are risk factors for
Fig. 3 Resected specimen of the patient. Pathological examination revealed no viable cancer cells remaining in the specimen
Fig. 2 Laparoscopic studies of the patient. Repeat laparoscopy is showing a disappearance of the peritoneal carcinomatosis. a Right upper
quadrant of the abdomen. b Left upper quadrant of the abdomen. c, d Lower part of the abdomen
Okuno et al. World Journal of Surgical Oncology  (2016) 14:107 Page 3 of 5
gastric cancer resulting in DCBM [5, 6, 10]. Of note,
many cases (66.7 %) recur over 5 years following the
initial surgery, with recurrence at the bone marrow
more than 10 years as reported in some case [11, 12],
indicating the presence of “tumor dormancy,” a long la-
tent phase of tumor progression [13]. The present case
matched most of these risk factors and presented all
major symptoms described in the literature in the
2 months after presenting with lumbago.
DCBM is associated with a poor prognosis, with some
patients dying within a few weeks as a result of bleeding
or organ insufficiency caused by DIC [5, 6, 10]. Park et
al. examined 203 cases of bone marrow metastasis
originating from gastric cancer. They found that the
median survival time was 103 days, with complicated
DIC being associated with a significantly poorer progno-
sis, while patients receiving chemotherapy had a better
prognosis (175 days). On the other hand, the median
survival time of the patients who did not receive chemo-
therapy was only 43 days [14], indicating that aggressive
chemotherapy is effective for DCBM [10–12]. In this
case, we changed the regimen to weekly CPT-11 because
the patient had already received other key drugs for gas-
tric cancer, including S-1, cisplatin, and PTX. The pa-
tient overcame DIC once and survived for 6 months
after the diagnosis of DCBM.
In our previous clinical studies, we treated peritoneal
carcinomatosis of gastric cancer using intraperitoneal
chemotherapy with PTX. In this intraperitoneal che-
motherapy, PTX is repeatedly administered into the
intraperitoneal space via a subcutaneously placed intraper-
itoneal access port. This combination chemotherapy is
effective for peritoneal metastases and appears to produce
a marked elongation of survival in these patients [1–3].
Moreover, peritoneal carcinomatosis often disappears
macroscopically during the course of intraperitoneal
chemotherapy. From August 2005 to April 2012, 158
cases of gastric cancer with peritoneal carcinomatosis
underwent intraperitoneal chemotherapy with PTX in our
department. Recurrence in the bone was found in 15 cases
(9.5 %), with multiple bones implicated in 4 cases (2.5 %);
of these, 3 cases (1.8 %) were clinically suspected as
DCBM with DIC. Two of these three cases (with the
exception of the present case) were treated with best
supportive care and died within 1 month. The higher
rate of DCBM experienced in our department compared
with that in previous reports may be due to the strong
suppression of peritoneal carcinomatosis by intraperito-
neal administration of PTX.
Conclusions
We here experienced a patient of gastric cancer with
peritoneal carcinomatosis who developed DCBM
3 years after initiation of intraperitoneal chemotherapy
with PTX. Since intraperitoneal PTX administration can
strongly suppress peritoneal carcinomatosis of gastric
cancer, careful attention should be paid not only to
peritoneal recurrence but also for rare site metastases,
such as bone marrow metastases, during the course
of intraperitoneal chemotherapy.
Fig. 4 a, b Bone scintigraphy and c fluorodeoxyglucose-positron emission tomography of the patients. Multiple bone metastases to the thoracic
to lumbar vertebrae, costae, sternum, iliac bone, scapulae, and femora are shown, suggestive of disseminated carcinomatosis of the bone marrow
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